Imeglimin is primarily used in the treatment of type 2 diabetes mellitus. It works by improving insulin secretion from pancreatic beta cells, enhancing insulin sensitivity in peripheral tissues, and reducing excessive glucose production in the liver. This triple mechanism of action helps in effectively managing blood glucose levels. Imeglimin is often prescribed as part of a comprehensive diabetes management plan, which may include diet, exercise, and other medications. It is particularly beneficial for patients who require an additional therapeutic option to achieve glycemic control. The drug is generally well-tolerated, making it a suitable choice for long-term management of diabetes.